<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237821</url>
  </required_header>
  <id_info>
    <org_study_id>CS1007033A</org_study_id>
    <nct_id>NCT01237821</nct_id>
  </id_info>
  <brief_title>Comparing OTC Acne Treatment to Prescription Regimen</brief_title>
  <official_title>A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loreal USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out the safety and efficacy of two acne creams, Effaclar
      and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are  FDA
      approved for the treatment of acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many products on the market to treat facial acne. The medication that this study
      will be evaluating, Benzaclin and Retin-A have been approved by the FDA and is available by
      prescription, Effaclar is an over the counter product. This study will hopefully recognize a
      treatment combination that is effective in reducing acne vulgaris in adults 18-50.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acne</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A multi-center, double-blind clinical trial to evaluate the safety and efficacy of two acne creams in subjects with mild to moderate acne vulgaris</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BenzaClin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with &gt; or equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>effaclar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with &gt; or equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BenzaClin</intervention_name>
    <description>Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks</description>
    <arm_group_label>BenzaClin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Effaclar</intervention_name>
    <description>Topical, Bid, 12 weeks</description>
    <arm_group_label>effaclar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:males and females ages 18-50, mild to moderate acne vulgaris with &gt; or
        equal to 15 inflammatory lesions, &gt; or equal to 20 non-inflammatory lesions, avoid
        excessive sun exposure or tanning beds throughout the study

        Exclusion Criteria:Participants who have another skin condition that will interfere with
        lesion counting or assessments
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Oresajo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loreal USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>November 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Amy Longenecker</investigator_full_name>
    <investigator_title>RN, CCRC</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
